Perinatal HIV transmission: Developing country considerations

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 12, Issue 3, 2002, Pages 149-158

  Goldenberg, R L ^a   Stringer, J S A ^a   Sinkala, M ^a   Vermund, S H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Developing countries; Human immunodeficiency virus; Perinatal transmission

Indexed keywords

ANTIVIRUS AGENT; NEVIRAPINE; ZIDOVUDINE;

BREAST FEEDING; CHILDHOOD MORTALITY; CLINICAL TRIAL; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG COST; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFANT MORTALITY; INFECTION CONTROL; PERINATAL INFECTION; PLACENTAL TRANSFER; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; VIRUS TRANSMISSION;

EID: 0036744836     PISSN: 14767058     EISSN: None     Source Type: Journal    
DOI: 10.1080/jmf.12.3.149.158     Document Type: Review

References (85)

1. Gray G, McIntyre J, Newell M-L. HIV-1 infection. In Newell M-L, McIntyre J, eds. Congenital and Perinatal Infections: Prevention, Diagnosis and Treatment. Cambridge, UK: Cambridge University Press, 2000:232-57
2. Mertens TE, Belsey E, Stoneburner RL, et al. Global estimates and epidemiology of HIV-1 infections and AIDS: further heterogeneity in spread and impact. AIDS 1995;9:S259-72
3. Blattner WA, O'Brien TR, Mueller NE. Retroviruses - human immunodeficiency viruses. In Evans AS, Kaslow RA, eds. Viral Infections of Humans: Epidemiology and Control. New York: Plenum Medical Book Company, 1997:713-83
4. Blank A, Mofenson LM, Willoughby A, et al. Maternal and pediatric AIDS in the United States: the current situation and future research directions. Acta Paediatr Suppl 1994;400:106-10
5. European Collaborative Study. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet 1991;337:253-60
6. Centers for Disease Control and Prevention. Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. Morbid Mortal Weekly Rep 1998;47:43-62
7. Panel on Clinical Practices for Transmission of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available from URL: http://www.hivatis.org. Accessed 5 February 2001
8. De Vincenzi I, for the European Study Group on Heterosexual Transmission of HIV. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. N Engl J Med 1991;331:341-6
9. Cameron DW, D'Costa LJ, Maitha GM, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in man. Lancet 1989;19:403-7
10. Keenlyside R, Johnson AM, Mabey DCW. The epidemiology of HIV-1 infection and AIDS in women. AIDS 1993;7:583-90
11. De Martino M, Tovo P-A, Tozzi AE, et al. HIV-1 transmission through breastmilk: appraisal of risk according to duration of feeding. AIDS 1992;6:991-7
12. Peterman TA, Stonebrunner RL, Allen JR, et al. The risk of human immunodeficiency virus transmission from heterosexual adults with transfusion associated infections. J Am Med Assoc 1988;259:55-8
13. Hanenberg RS, Rojanapithayakorn W, Kunasol P, et al. Impact of Thailand's HIV-control programme as indicated by the decline in sexually transmitted diseases. Lancet 1994;344:243-5
14. Asiimwe-Okiror G, Opio AA, Musinguzi J, et al. Change in sexual behaviour and decline in HIV infection among young pregnant women in urban Uganda. AIDS 1997;11:757-63
15. Graham WJ, Newell M-L. Seizing the opportunity: collaborative initiatives to reduce HIV and maternal mortality. Lancet 1999;353:836-9
16. Kelly JA. Community-level interventions are needed to prevent new HIV infections. Am J Public Health 1999;89:299-301
17. Mofenson LM. Mother-child HIV-1 transmission: timing and determinants. Obstet Gynecol Clin North Am 1997;24:759-84
18. Kourtis AP, Bulterys M, Nesheim SR, et al. Understanding the timing of HIV transmission from mother to infant. J Am Med Assoc 2001;285:709-12
19. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80
20. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484-94
21. Lindegren ML, Byers RH Jr, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. J Am Med Assoc 1999;282:531-8
22. Watts DH. Management of human immunodeficiency virus infection in pregnancy. N Engl J Med 2002;346:1879-91
23. Rouse DJ, Owen J, Goldenberg RL, et al. Zidovudine for the prevention of vertical HIV transmission: a decision analytic approach. J Acquir Immune Defic Syndr 1995;9:401-7
24. Culnane M, Fowler M, Lee S, et al. Lack of long-term effects of in-utero exposure to zidovudine in children born to HIV-infected women. J Am Med Assoc 1999;281:151-7
25. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-9
26. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002;346:1863-70
27. Public Health Service Task Force Perinatal HIV Guidelines Working Group. Summary of the updated recommendations from the Public Health Service Task Force to reduce perinatal human immunodeficiency virus-1 transmission in the United States. Obstet Gynecol 2002:99:1117-26
28. World Health Organization. Section three. Guide to ART in resource limited settings. Available at: http://www.who.int/HIV_AIDS/WHO_HIS_2000.04_1.04/003.htm. Accessed 14 June 2002
29. Centers for Disease Control. Revised recommendations for HIV screening of pregnant women. Morbid Mortal Weekly Rep 2001;19:63-85
30. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-14
31. Mock PA, Shaffer N, Bhadrakom C, et al. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. AIDS 1999;13:407-14
32. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-9
33. Thea DM, Steketee RW, Pliner V, et al. The effect of maternal viral load on the risk of perinatal transmission of HIV-1. J Infect Dis 1997;175:707-11
34. Mandelbrot L, Mayaux M-J, Bongain A, et al., and The French Pediatric HIV Infection Study Group. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. Am J Obstet Gynecol 1996;175:661-7
35. Minkoff H, Mofenson LM. The role of obstetric interventions in the prevention of pediatric human immunodeficiency virus infection. Am J Obstet Gynecol 1994;171:1167-75
36. Youchah J, Minkoff H, Landesman S, et al. Longer duration of ruptured membranes is associated with increased risk of vertical transmission of HIV infection. Am J Obstet Gynecol 1994;170:415
37. Minkoff H, Burns DN, Landesman S, et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol 1995;173:585-9
38. Taha TE, Gray RH. Genital tract infections and perinatal transmission of HIV. Ann NY Acad Sci 2000;918:84-98
39. Turner BJ, Hauck WW, Fanning R, et al. Cigarette smoking and maternal-child HIV transmission. J Acquir Immune Defic Syndr Human Retrovirol 1997;14:327-37
40. + levels. J AIDS 1994;7:718-26
41. Fawzi W, Msamanga G, Renjifo B, et al. Predictors of intrauterine and intrapartum transmission of HIV-1 among Tanzanian women. AIDS 2001;15:1157-65
42. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998;12:F241-7
43. Fowler MG, Mofenson L. Progress in prevention of perinatal HIV-1. Acta Paediatri 1997;421:97-103
44. Melvin AJ, Burchett SK, Watts DH, et al. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:232-6
45. The European Mode of Delivery Collaboration. Elective Caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. Lancet 1999;353:1035-9
46. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340:977-87
47. Stringer JSA, Rouse DJ, Goldenberg RL. Prophylactic Cesarean for the prevention of perinatal HIV transmission: the case for restraint. J Am Med Assoc 1999;281:1946-9
48. Wiktor SZ, Ekpini E, Nduati RW. Prevention of mother-to-child transmission of HIV-1 in Africa. AIDS 1997;11:S79-87
49. Miotti PG, Taha TE, Kumwenda NI, et al. HIV transmission through breastfeeding: a study in Malawi. J Am Med Assoc 1999;282:744-9
50. Bertolli J, St Louis ME, Simonds RJ, et al. Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire. J Infect Dis 1996;174:722-6
51. Leroy V, Newell ML, Dabis F, et al. International multicentre pooled analysis of later postnatal mother-to-child transmission of HIV-1 infection. Lancet 1998;352:597-600
52. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. Lancet 2000;355:451-5
53. Nduati R, John G, Ngacha DA, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomised clinical trial. J Am Med Assoc 2000;283:1167-4
54. Coutsoudis A, Pillay K, Spooner E, et al., for the South African Vitamin A Study Group. Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. Lancet 1999;354:471-6
55. Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2000;181:93-8
56. Nicoll A, Newell ML, Van Praag E, et al. Infant feeding policy and practice in the presence of HIV-1 infection. AIDS 1995;9:107-19
57. Ndauti R, Richardson BA, John G, et al. Effect of breastfeeding on mortality among HIV-1 infected women: a randomised trial. Lancet 2001;357:1651-5
58. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission of HIV-1 in breastfed African children. Lancet 2000;283:1175-82
59. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999;353:773-80
60. Saba J. Current status of PETRA study. Presented at the 2nd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants, Montreal, Quebec, 2 September 1999
61. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999;353:781-5
62. Dabis F, Msellati P, Meda N, et al. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999;353:786-92
63. Limpongsanurak S, Thaithumyanon P, Thisyakorn U, et al. Intrapartum zidovudine infusion alone failed to reduce both maternal HIV-1 viral load and HIV-1 infection in infant. J Med Assoc Thailand 2001;84:611-16
64. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802
65. O'Sullivan MJ, Boyer PJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Am J Obstet Gynecol 1993;168:1510-16
66. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999;13:479-86
67. Gordon M, Haddix AC, Steketee RW, et al. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African developing country setting. J Am Med Assoc 1996;276:139-45
68. Marseille E, Kahn JG, Miro F, et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 1999;354:803-9
69. Newell ML, Dabis F, Tolley K, et al. Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries. AIDS 1998;12:1571-80
70. Soderlund N, Zwi K, Kinghorn A, et al. Prevention of vertical transmission of HIV: analysis of cost effectiveness of options available in South Africa. Br Med J 1999;318:1650-6
71. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis 1998;178:368-94
72. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-7
73. Stringer JSA, Rouse DJ, Goldenberg RL, et al. Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa. J AIDS 2000;24:369-77
74. Stringer JSA, Sinkala M, Goldenberg RL, et al. A prospective comparison of two strategies for perinatal nevirapine administration in Zambia. Oral Presentation at the 3rd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants, Kampala, Uganda, 9-13 September 2001 (abstr 303)
75. Abdullah MF, Young T, Bitalo L, et al. Public health lessons from a pilot programme to reduce mother-to-child transmission of HIV-1 in Khayelitsha. S Afr Med J 2001;91:579-83
76. Nogueira SA, Abreu T, Oliveira R, et al. Successful prevention of HIV transmission from mother to infant in Brazil using a multidisciplinary team approach. Braz J Infect Dis 2001;5:78-86
77. Biggar RJ, Miotti PG, Taha TE, et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 1996;347:1647-50
78. Gaillard P, Mwanyumba F, Verhofstede C, et al. Vaginal lavage with chlorhexidine during labour to reduce mother-to-child HIV transmission: clinical trial in Mombasa, Kenya. AIDS 2001;15:389-96
79. Fawzi WW, Msamanga GI, Spiegelman D, et al. Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania. Lancet 1998;351:1477-82
80. Gray RH, Wabwire-Mangen F, Kigozi G, et al. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. Am J Obstet Gynecol 2001;185:1209-17
81. Taha TE, Biggar RJ, Broadhead RL, et al. Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: clinical trial. Br Med J 1997;315:216-19
82. Schoofs M. AIDS: the agony of Africa. Part 1: The virus creates a generation of orphans. The Village Voice [serial online]. Available from URL: http://www.villagevoice.com/issues/9944/schoofs.shtml. Accessed 3-9 November 1999
83. Foster G. Supporting community efforts to assist orphans in Africa. N Engl J Med 2002;346:1907-10
84. Goldenberg RL, Vermund SH, Goepfert A, et al. Choriodecidual inflammation: a potentially preventable cause of perinatal HIV transmission? Lancet 1998;352:1927-30
85. World Health Organization. HIV in Pregnancy: a Review. UNAIDS 99.35.E. Geneva: World Health Organization, 1999